KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $8.9 million.

  • Inovio Pharmaceuticals' Cash from Investing Activities fell 3701.25% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.7 million, marking a year-over-year decrease of 4546.06%. This contributed to the annual value of $104.1 million for FY2024, which is 1913.46% up from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Cash from Investing Activities of $8.9 million as of Q3 2025, which was down 3701.25% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Cash from Investing Activities peaked at $56.0 million during Q3 2021, and registered a low of -$275.1 million during Q1 2021.
  • In the last 5 years, Inovio Pharmaceuticals' Cash from Investing Activities had a median value of $19.0 million in 2023 and averaged $7.4 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Cash from Investing Activities tumbled by 43101.9% in 2021 and then surged by 93155.0% in 2022.
  • Inovio Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$6.5 million in 2021, then soared by 931.55% to $54.0 million in 2022, then crashed by 63.07% to $19.9 million in 2023, then soared by 73.71% to $34.6 million in 2024, then plummeted by 74.4% to $8.9 million in 2025.
  • Its Cash from Investing Activities stands at $8.9 million for Q3 2025, versus $5.3 million for Q2 2025 and -$51753.0 for Q1 2025.